PMM2-congenital disorder of glycosylation
MONDO:0008907The most frequent form of congenital disorder of N-glycosylation and is characterized by cerebellar dysfunction, abnormal fat distribution, inverted nipples, strabismus and hypotonia. 3 forms of PMM2-CDG can be distinguished: the infantile multisystem type, late-infantile and childhood ataxia-intellectual disability type (3-10 yrs old), and the adult stable disability type. Infants usually develop ataxia, psychomotor delay and extraneurological manifestations including failure to thrive, enteropathy, hepatic dysfunction, coagulation abnormalities and cardiac and renal involvement. The phenotype is however highly variable and ranges from infants who die in the first year of life to mildly involved adults.
Also known as: CDG 1A, CDG syndrome type Ia, CDG-IA, CDG1A, PMM2-CDG, PMM2-congenital disorder of glycosylation, carbohydrate deficient glycoprotein syndrome type Ia, congenital disorder of glycosylation type 1a
5 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Experimental drug GLM101 targets rare PMM2-CDG in pivotal trial
Disease control OngoingThis study tests a drug called GLM101 for people with PMM2-CDG, a rare inherited disease that affects movement and coordination. About 50 children and adults will receive weekly infusions of either GLM101 or a placebo for 24 weeks, followed by an open-label phase where everyone g…
Phase: PHASE2, PHASE3 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Hope for rare disease: new drug shows promise in Long-Term study
Disease control ENROLLING_BY_INVITATIONThis study is for people with PMM2-CDG, a rare genetic disorder, who have already taken the experimental drug GLM101 in a previous trial. The goal is to see if GLM101 is safe and effective over a longer period. Participants will receive weekly infusions of GLM101 at the same dose…
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC